7 mad mdcpt

7-MAD-MDCPT is a Camptothecin derivative, which often acts as a cytotoxic load in antibody drug conjugate (ADC).

Mal-Bal-Ph(β-D-Glucose)-7-MAD-MDCPT serves as a drug-linker conjugate for ADC (antibody-drug conjugate) synthesis.

7-MAD-MDCPT TFA is a Camptothecin analog that serves as the active component in antibody-drug conjugates (ADC).

Gly-7-MAD-MDCPT (Compound 4b) hydrochloride is an anticancer agent. As a Camptothecin compound, Gly-7-MAD-MDCPT hydrochloride exhibits cytotoxicity against various cancer cells, with an IC50 ranging from 10 to 1000 nM.

7-MAD-MDCPT hydrochloride, a camptothecin analogue, serves as the active component in antibody-drug conjugates (ADC).

Gly-7-MAD-MDCPT (Compound 4b) TFA is an anticancer agent. This Camptothecin compound exhibits cytotoxicity against various cancer cell lines, with an IC50 range of 10-1000 nM.

TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). It consists of a topoisomerase 1 (topoisomerase1) inhibitor known as Topi MF-6 and a cleavable linker (Maleimide-Ph(3,5-F)-PEG4-Val-Ala). This compound is used for the synthesis of ADCs.

MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a Camptothecin-linker and a drug-linker conjugate for antibody-drug conjugate (ADC).

Gly-7-MAD-MDCPT is an anticancer agent. Gly-7-MAD-MDCPT is a Camptothecin compound, it shows cytotoxicity to various cancer cells with IC 50 values of 10-1000 nM [1] .

Compound I, NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT, is a topoisomerase I inhibitor with the capability for targeted delivery to cells via conjugated antibodies. It exhibits effective ADC activity both in vivo and in vitro [1].

Compound I, NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT hydrochloride, is a topoisomerase I inhibitor that demonstrates effective antibody-drug conjugate (ADC) activity both in vivo and in vitro, with delivery to cells facilitated through targeted antibody conjugation [1].

MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT is an agent-linker conjugate designed for antibody-drug conjugate (ADC) applications, with potential use in cancer and autoimmune disease research.

7-MAD-MDCPT-AC-(s-cyclopropane) is a derivative of camptothecin. It can be linked to monoclonal antibodies via a linker to form an antibody-drug conjugate (ADC). This compound is applicable in cancer research.

ABBV-969 Payload (Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT) is a drug-linker conjugate employed in the synthesis of antibody-drug conjugates (ADCs). The ABBV-969 Payload contains a Topoisomerase I inhibitor molecule and a chemical linker, enabling coupling with anti-c-Met antibodies to generate ABBV-969 ADCs with targeted anticancer activity.

DBCO-PEG8-VKG-CPT2 is a drug-linker conjugate for ADCs, consisting of a topoisomerase 1 inhibitor (7-MAD-MDCPT) and a stable cleavable linker (DBCO-PEG8-VKG). This compound is applicable for the synthesis of ADCs.

Telisotuzumab Adizutecan (ABBV-400) is an antibody-drug conjugate (ADC) targeting c-Met. It consists of the humanized anti-c-Met antibody Telisotuzumab, a stable cleavable linker (TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane), and a topoisomerase 1 inhibitor (7-MAD-MDCPT). The drug-linker conjugate of the ADC is TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT. Telisotuzumab Adizutecan exhibits significant antitumor activity against advanced solid tumors such as colorectal, gastric, and non-small cell lung cancers.